Fast-growing tumors keel over in the face of Herceptin combined with chemotherapy--sometimes so completely that mastectomy wasn't necessary. Such are the late-stage study results that Roche proudly announced today. Tumors disappeared completely in 55 percent of the study patients, and from the breast and lymph nodes in 48 percent.
No specifics on side effects, just the standard assurance that treatment was "well tolerated," with an addendum that cardiac safety was "acceptable." We'll have to wait until the study wraps to find out more.
- see Roche's release on Herceptin
Related Articles:
Roche files for expanded use of Herceptin. Report
Genentech wins approval for new Herceptin indication. Report
Blocking enzyme effective in preventing breast cancer. Report
JCO warns on radiation, Herceptin. Report